Monopar Therapeutics (NASDAQ:MNPR) Director Raymond Anderson Sells 3,142 Shares of Company Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $68.35, for a total transaction of $214,755.70. Following the transaction, the director directly owned 5,373 shares in the company, valued at $367,244.55. The trade was a 36.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raymond Anderson also recently made the following trade(s):

• On Tuesday, August 25th, Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $72.81 on Thursday. Monopar Therapeutics Inc. has a 52-week low of $50.07 and a 52-week high of $124.82. The company has a 50-day simple moving average of $88.66 and a two-hundred day simple moving average of $77.40. The company has a market capitalization of $488.56 million, a price-to-earnings ratio of -33.55 and a beta of 1.62.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. On average, sell-side analysts forecast that Monopar Therapeutics Inc. will post -2.98 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on MNPR shares. UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Barclays reissued an “overweight” rating and issued a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. HC Wainwright increased their price target on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. Finally, Morgan Stanley restated an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.00.

Monopar Therapeutics News Summary

Here are the key news stories impacting Monopar Therapeutics this week:

• Neutral Sentiment: Monopar is projected to announce quarterly earnings on Thursday. The report could give investors an update on the company’s performance; no results or estimates are detailed in the article. Monopar Therapeutics projected to announce quarterly earnings
• Neutral Sentiment: A separate article raises the question of what investment firms think about MNPR, but the provided information does not specify any firms’ ratings, price targets, or recent actions. What investment firms are thinking about MNPR
• Negative Sentiment: Directors reported selling shares: Kim Tsuchimoto sold 2,891 shares on Nov. 4 and 1,199 on Nov. 2, while Raymond Anderson sold 3,142 shares on Nov. 2. The sales reduced their reported holdings and could concern investors, although the transactions were made under pre-arranged Rule 10b5-1 plans. SEC filing for director transactions

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently made changes to their positions in the company. Your Advocates Ltd. LLP bought a new stake in Monopar Therapeutics in the 1st quarter valued at about $183,000. The Manufacturers Life Insurance Company purchased a new stake in Monopar Therapeutics during the first quarter valued at about $250,000. Sei Investments Co. boosted its position in Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares during the period. Bank of America Corp DE boosted its position in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares during the period. Finally, Walleye Capital LLC bought a new position in Monopar Therapeutics during the first quarter worth about $3,458,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.